Regnault Véronique, Béguin Suzette, Lecompte Thomas
INSERM ERIT-M 0323 et EA 3452, Faculté de Médecine, Université Henri Poincaré, CHU de Nancy, Nancy, France.
Pathophysiol Haemost Thromb. 2003;33(1):23-9. doi: 10.1159/000071638.
To enhance the practical applicability of the calibrated automated thrombogram (CAT) we investigated whether frozen-thawed platelet-rich plasma (ft-PRP) can be used to assess the function of the protein C inhibitory pathway, while preserving the natural phospholipid composition. Recalcified ft-PRP triggered with 0.5 pM recombinant human tissue factor shows a median thrombin potential of 1,779 nM x min, against 1,576 nM x min for fresh PRP. To obtain approximately 70% inhibition, 6.7 nM activated protein C (APC) has to be added, instead of 25 nM in fresh PRP; so the relative APC resistance of PRP appears to depend upon the presence of intact platelets. Factor VIII, added to normal ft-PRP to obtain a concentration of 3.3 U/ml, increases the thrombin potential in the presence of APC 1.5-fold, from 524 to 808 nM x min, in keeping with previously published increases in thrombotic risk in patients with high factor VIII levels. We conclude that thrombography in ft-PRP, with and without added APC, can be used to assess known risk factors for thrombosis, which allows the design of large clinical studies aimed at proving the relationship between thrombin potential and clinical outcome.
为提高校准自动血栓图(CAT)的实际适用性,我们研究了冻融富血小板血浆(ft-PRP)能否用于评估蛋白C抑制途径的功能,同时保留天然磷脂成分。用0.5 pM重组人组织因子触发重新钙化的ft-PRP,其凝血酶潜力中位数为1779 nM·min,而新鲜PRP为1576 nM·min。为获得约70%的抑制率,必须添加6.7 nM活化蛋白C(APC),而新鲜PRP中为25 nM;因此PRP的相对APC抵抗似乎取决于完整血小板的存在。向正常ft-PRP中添加因子VIII使其浓度达到3.3 U/ml,在存在APC的情况下,凝血酶潜力增加1.5倍,从524 nM·min增加到808 nM·min,这与先前发表的因子VIII水平高的患者血栓形成风险增加一致。我们得出结论,在添加和不添加APC的ft-PRP中进行血栓图分析,可用于评估已知的血栓形成风险因素,这有助于设计大型临床研究以证明凝血酶潜力与临床结果之间的关系。